Celldex Therapeutics Slides 12% Below Year‑High, Yet Holds Mid‑Cap Upside Potential
Celldex Therapeutics’ share slide to $29.37 as investors await new clinical data and financial updates; despite a 12% dip, the mid‑cap biotech may still offer upside.
- CELLDEX THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read